About
Anand Mehra, M.D., joined Sofinnova Ventures in 2007 as a Principal to focus on biopharmaceutical investing. Anand's diverse background equips him to work with entrepreneurs on scientific, clinical, and strategic levels. Currently, Anand is a director of Marinus Pharmaceuticals, active in Anthera and Prestwick Pharmaceuticals, and played an instrumental role in the firm's investments in Hyperion and PregLem. Prior to joining Sofinnova Ventures, Anand worked in JP Morgan's private equity and venture capital group, where he was heavily involved in investments made in Phenomix, Kemia, and CardioKinetix, management of their public portfolio, and the firm's spin-out from the bank. Before joining the venture community, Anand was a consultant in McKinsey & Company's pharmaceutical practice, advising pharma and biotech on key strategic issues, and an NIH-funded Fellow focused on reperfusion injury in stroke. Anand received his M.D. from Columbia Medical School and graduated Phi Beta Kap
Position in the VCSift Database
- • 2 investors at Merus are tracked.
- • 4 investors hold the Board Chair role in VCSift. Anand Mehra is one of them.
- • 7,285 investors are based in San Francisco, California, United States.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Location
- San Francisco, US
Contact Information
Find more investors like Anand
Search Investors